Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
University of Colorado, Denver
With
National Heart, Lung, and Blood Institute (NHLBI)
Age
5–17
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
5 to 17 years of age (inclusive) presenting to the ED with an asthma exacerbation
Prior diagnosis of asthma by a physician who prescribed asthma medications (beta-agonist and/or inhaled or oral steroids)
PRAM score of 4 or greater after administration of first-line therapy (albuterol/ipratropium back to backs, corticosteroids, +/- oxygen) and need for continuous beta-agonist therapy after first-line therapy
You may not be if
Prior participation in the study
Hypercapnic (PaCO2 \> 60 mmHg) respiratory failure or need for invasive mechanical ventilation as determined by the treating physician
Hypoxemic respiratory failure (SaO2 \< 90% with fraction of inspired oxygen inspired oxygen fraction (FiO2) \> 0.35)
Presence of a tracheostomy or baseline noninvasive ventilation requirement
Absolute or relative contraindication to BiPAP: facial trauma, uncontrollable vomiting, hypotension for age, Glasgow Coma Score of 8 or less, drowsiness or confusion, known or clinical suspicion for pneumothorax, pneumomediastinum, or subcutaneous emphysema, pregnancy
Clareo Health | BiPAP in Pediatric Moderate to Severe Asthma Randomized Control Trial
